CapVest Partners LLP has completed its acquisition of a majority stake in STADA Arzneimittel AG, a global healthcare and pharmaceuticals company focused on consumer healthcare, generics, and specialty pharmaceuticals.
The transaction follows strong financial performance by STADA in 2025 and is expected to support the company’s next phase of global expansion. Both CapVest and STADA plan to accelerate growth through organic initiatives and strategic acquisitions.
Headquartered in Bad Vilbel, Germany, STADA operates in more than 100 countries and employs nearly 12,000 people worldwide. The company reported record revenues of €4.3 billion in 2025, representing a 6% increase year over year, along with adjusted EBITDA of €961 million.
CapVest, an international private equity firm, focuses on investing in resilient industries such as healthcare, consumer staples, and essential services. The firm aims to scale portfolio companies through operational improvements and acquisition-led growth.
The acquisition was finalized after receiving all necessary regulatory approvals and meeting customary closing conditions. With the deal now complete, both organizations will work closely to expand STADA’s global footprint and strengthen its position across key pharmaceutical segments, including biosimilars and innovative medicines.
KEY QUOTES:
“We are delighted the transaction has now completed. CapVest’s deep knowledge and experience in healthcare, as well as their commitment to supporting our continued growth ambitions, will be a great asset as we look to realise our exciting plans for the business.”
Peter Goldschmidt, Chief Executive Officer of STADA Arzneimittel AG
“While we have worked to complete this transaction, the STADA team has continued to demonstrate strong growth across key regions and consumer healthcare, generics, biosimilars and innovative medicines. We are excited to now be in a position to work actively with the team to deliver our ambitious shared plans for the business.”
Matt Fargie, Partner at CapVest Partners LLP
